VanEck Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $56.4M | Sell |
259,354
-11,994
| -4% | -$2.66M | 0.04% | 254 |
|
|
2025
Q4 | $62M | Buy |
271,348
+131,515
| +94% | +$30M | 0.05% | 215 |
|
|
2025
Q3 | $32.4M | Sell |
139,833
-27,126
| -16% | -$5.52M | 0.03% | 276 |
|
|
2025
Q2 | $31M | Sell |
166,959
-63,645
| -28% | -$11.8M | 0.04% | 274 |
|
|
2025
Q1 | $48.3M | Sell |
230,604
-26,909
| -10% | -$5.23M | 0.06% | 196 |
|
|
2024
Q4 | $45.8M | Buy |
257,513
+5,863
| +2% | +$1.08M | 0.06% | 189 |
|
|
2024
Q3 | $47.3M | Buy |
251,650
+25,248
| +11% | +$4.71M | 0.06% | 180 |
|
|
2024
Q2 | $38.8M | Buy |
226,402
+9,105
| +4% | +$1.51M | 0.06% | 191 |
|
|
2024
Q1 | $39.6M | Buy |
217,297
+49,284
| +29% | +$8.49M | 0.06% | 186 |
|
|
2023
Q4 | $26M | Sell |
168,013
-893
| -0.5% | -$130K | 0.05% | 204 |
|
|
2023
Q3 | $25.2M | Buy |
168,906
+10,015
| +6% | +$1.47M | 0.06% | 199 |
|
|
2023
Q2 | $21.4M | Buy |
158,891
+1,537
| +1% | +$225K | 0.05% | 229 |
|
|
2023
Q1 | $25.1M | Sell |
157,354
-65,003
| -29% | -$9.94M | 0.06% | 214 |
|
|
2022
Q4 | $35.9M | Sell |
222,357
-73,685
| -25% | -$11.3M | 0.09% | 174 |
|
|
2022
Q3 | $39.7M | Buy |
296,042
+20,135
| +7% | +$2.89M | 0.12% | 158 |
|
|
2022
Q2 | $42.3M | Buy |
275,907
+45,678
| +20% | +$6.98M | 0.11% | 172 |
|
|
2022
Q1 | $37.3M | Buy |
230,229
+12,513
| +6% | +$1.82M | 0.08% | 196 |
|
|
2021
Q4 | $29.5M | Sell |
217,716
-15,023
| -6% | -$1.77M | 0.07% | 214 |
|
|
2021
Q3 | $25.1M | Buy |
232,739
+59,097
| +34% | +$6.75M | 0.06% | 224 |
|
|
2021
Q2 | $19.6M | Sell |
173,642
-210,029
| -55% | -$23.7M | 0.05% | 253 |
|
|
2021
Q1 | $41.5M | Buy |
383,671
+7,930
| +2% | +$848K | 0.11% | 161 |
|
|
2020
Q4 | $40.3M | Buy |
375,741
+186,084
| +98% | +$17.9M | 0.12% | 147 |
|
|
2020
Q3 | $16.6M | Sell |
189,657
-5,900
| -3% | -$555K | 0.05% | 203 |
|
|
2020
Q2 | $19.2M | Buy |
195,557
+14,813
| +8% | +$1.3M | 0.07% | 181 |
|
|
2020
Q1 | $13.8M | Sell |
180,744
-18,110
| -9% | -$1.54M | 0.07% | 176 |
|
|
2019
Q4 | $17.6M | Buy |
198,854
+28,163
| +16% | +$2.34M | 0.07% | 190 |
|
|
2019
Q3 | $12.9M | Sell |
170,691
-3,466
| -2% | -$238K | 0.06% | 194 |
|
|
2019
Q2 | $12.7M | Sell |
174,157
-4,105
| -2% | -$323K | 0.06% | 207 |
|
|
2019
Q1 | $14.4M | Sell |
178,262
-3,788
| -2% | -$310K | 0.07% | 191 |
|
|
2018
Q4 | $16.8M | Sell |
182,050
-255
| -0.1% | -$22.4K | 0.08% | 181 |
|
|
2018
Q3 | $17.2M | Buy |
182,305
+7,806
| +4% | +$740K | 0.08% | 197 |
|
|
2018
Q2 | $16.2M | Buy |
174,499
+65,367
| +60% | +$6.38M | 0.08% | 194 |
|
|
2018
Q1 | $10.3M | Sell |
109,132
-33,650
| -24% | -$3.7M | 0.05% | 232 |
|
|
2017
Q4 | $13.8M | Sell |
142,782
-36,237
| -20% | -$3.42M | 0.07% | 207 |
|
|
2017
Q3 | $15.9M | Sell |
179,019
-21,263
| -11% | -$1.62M | 0.08% | 194 |
|
|
2017
Q2 | $14.5M | Sell |
200,282
-59,995
| -23% | -$4.03M | 0.08% | 195 |
|
|
2017
Q1 | $17M | Buy |
260,277
+44,523
| +21% | +$2.8M | 0.07% | 181 |
|
|
2016
Q4 | $13.5M | Buy |
215,754
+31,015
| +17% | +$1.89M | 0.07% | 181 |
|
|
2016
Q3 | $11.7M | Sell |
184,739
-29,755
| -14% | -$1.93M | 0.05% | 193 |
|
|
2016
Q2 | $13.3M | Sell |
214,494
-15,827
| -7% | -$964K | 0.07% | 173 |
|
|
2016
Q1 | $13.2M | Sell |
230,321
-61,244
| -21% | -$3.41M | 0.09% | 146 |
|
|
2015
Q4 | $17.3M | Buy |
291,565
+9,932
| +4% | +$572K | 0.14% | 146 |
|
|
2015
Q3 | $15.3M | Sell |
281,633
-2,833
| -1% | -$184K | 0.12% | 147 |
|
|
2015
Q2 | $19.1M | Buy |
284,466
+24,912
| +10% | +$1.63M | 0.11% | 148 |
|
|
2015
Q1 | $15.2M | Buy |
259,554
+17,416
| +7% | +$1.05M | 0.09% | 177 |
|
|
2014
Q4 | $15.8M | Sell |
242,138
-73,642
| -23% | -$4.64M | 0.1% | 161 |
|
|
2014
Q3 | $18.2M | Buy |
315,780
+36,314
| +13% | +$2.02M | 0.1% | 154 |
|
|
2014
Q2 | $15.8M | Sell |
279,466
-26,013
| -9% | -$1.36M | 0.07% | 163 |
|
|
2014
Q1 | $15.7M | Buy |
305,479
+65,142
| +27% | +$3.29M | 0.08% | 154 |
|
|
2013
Q4 | $12.7M | Sell |
240,337
-26,516
| -10% | -$1.3M | 0.06% | 167 |
|
|
2013
Q3 | $11.9M | Buy |
266,853
+13,587
| +5% | +$602K | 0.06% | 159 |
|
|
2013
Q2 | $10.5M | Buy |
+253,266
| New | +$11.1M | 0.06% | 165 |
|
Other funds holding ABBV
VCM
VPM
VanEck Associates's ABBV Position: Q1 2026 in Review
VanEck Associates reduced its AbbVie (ABBV) stake by 4.4% in Q1 2026, selling an estimated $2.66M and leaving 259,354 shares worth $56.4M. The position accounts for 0.04% of the portfolio, ranked #254.
VanEck Associates first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $62M in Q4 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- VanEck Associates held 259,354 shares of AbbVie worth $56.4M as of Q1 2026.
- VanEck Associates sold 11,994 AbbVie shares in Q1 2026, an estimated $2.66M.
- AbbVie made up 0.04% of VanEck Associates's portfolio in Q1 2026, its #254 holding.
- VanEck Associates first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
- VanEck Associates's AbbVie position peaked at $62M in Q4 2025.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.